Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B1430b76bb9c25562e4372245e31f3d0e> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B1430b76bb9c25562e4372245e31f3d0e NCIT_P378 "NCI" @default.
- B1430b76bb9c25562e4372245e31f3d0e type Axiom @default.
- B1430b76bb9c25562e4372245e31f3d0e annotatedProperty IAO_0000115 @default.
- B1430b76bb9c25562e4372245e31f3d0e annotatedSource NCIT_C156741 @default.
- B1430b76bb9c25562e4372245e31f3d0e annotatedTarget "A monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, manelimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells." @default.